Juluca Side Effects
Generic name: dolutegravir / rilpivirine
Medically reviewed by Drugs.com. Last updated on Apr 23, 2023.
Note: This document contains side effect information about dolutegravir / rilpivirine. Some dosage forms listed on this page may not apply to the brand name Juluca.
Applies to dolutegravir / rilpivirine: oral tablet.
Serious side effects of Juluca
Check with your doctor immediately if any of the following side effects occur while taking dolutegravir / rilpivirine:
- Abnormal dreams
- cloudy or bloody urine
- dark urine
- decreased frequency or amount of urine
- depressed mood
- gaseous stomach pain
- increased blood pressure
- increased thirst
- light-colored stools
- loss of appetite
- lower back or side pain
- recurrent fever
- severe nausea or vomiting
- stomach fullness or pain
- swelling of the face, fingers, feet, or lower legs
- thoughts or attempts at killing oneself
- trouble sleeping
- trouble breathing
- unusual tiredness or weakness
- upper right abdominal or stomach pain
- weight gain
- yellow eyes or skin
Incidence not known
- Black, tarry stools
- chest pain
- decreased appetite
- difficulty swallowing
- fast heartbeat
- painful or difficult urination
- skin itching, rash, or redness
- sore throat
- sores, ulcers, or white spots on the lips or in the mouth
- stomach tenderness
- stomach pain, continuing
- swelling of the face, throat, or tongue
- swollen glands
- unusual bleeding or bruising
Other side effects of Juluca
Some side effects of dolutegravir / rilpivirine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
- Bloated feeling
- excess air or gas in the stomach or bowels
- feeling of fullness
- muscle pain
- passing gas
- sleepiness or unusual drowsiness
Incidence not known
- Difficulty in moving
- joint pain or swelling
- muscle ache, cramp, or stiffness
For Healthcare Professionals
Applies to dolutegravir / rilpivirine: oral tablet.
In clinical trials, dolutegravir plus rilpivirine was discontinued due to side effects in 4% of patients. The most common side effects leading to discontinuation were psychiatric disorders.[Ref]
Very common (10% or more): Headache, dizziness
Common (1% to 10%): Somnolence
-Very common (10% or more): Headache
-Common (1% to 10%): Dizziness
-Common (1% to 10%): Headache, dizziness
-Uncommon (0.1% to 1%): Somnolence[Ref]
Very common (10% or more): Nausea, increased pancreatic amylase, diarrhea
-Very common (10% or more): Nausea, diarrhea
-Common (1% to 10%): Abdominal pain, vomiting, flatulence, upper abdominal pain, abdominal discomfort
-Common (1% to 10%): Abdominal pain, nausea, vomiting
-Uncommon (0.1% to 1%): Abdominal discomfort[Ref]
Grade 2 and grade 3 to 4 elevations in lipase were reported in 5% and 2% of patients, respectively.[Ref]
Very common (10% or more): Increased fasted total cholesterol, increased fasted low-density lipoprotein cholesterol
-Common (1% to 10%): Fatigue
-Postmarketing reports: Increased weight
-Common (1% to 10%): Fatigue[Ref]
Very common (10% or more): Insomnia
Uncommon (0.1% to 1%): Suicidal ideation, suicide attempt
Frequency not reported: Depressive disorders (including depressed mood, depression, suicidal ideation/attempt/behavior/completion)
-Common (1% to 10%): Insomnia, abnormal dreams, depression, anxiety
-Uncommon (0.1% to 1%): Suicidal ideation, suicide attempt
-Common (1% to 10%): Depression, insomnia, abnormal dreams, sleep disorders
-Uncommon (0.1% to 1%): Depressed mood[Ref]
Suicidal ideation or suicide attempt was reported, mainly in patients with history of depression or psychiatric illness.
Depressive disorders occurred primarily in patients with history of depression or other psychiatric illness.[Ref]
Grade 2 and grade 3 to 4 elevations in ALT were reported in 2% and less than 1% of patients, respectively. Grade 2 elevations in total bilirubin were reported in 2% of patients. Grade 2 and grade 3 to 4 elevations in AST were each reported in less than 1% of patients.
The incidence of liver chemistry elevations was higher in patients coinfected with hepatitis C than in those who were not coinfected.
In some patients using dolutegravir-containing regimens, elevations in transaminases were consistent with immune reconstitution syndrome or hepatitis B reactivation, especially when antihepatitis therapy was stopped.[Ref]
Very common (10% or more): Increased transaminases (elevated ALT and/or AST)
Common (1% to 10%): Elevated ALT, elevated total bilirubin
Uncommon (0.1% to 1%): Hepatitis
-Uncommon (0.1% to 1%): Hepatitis
-Frequency not reported: Elevations in transaminases (consistent with immune reconstitution syndrome or hepatitis B reactivation)
-Postmarketing reports: Acute liver failure, hepatotoxicity
-Common (1% to 10%): Increased transaminases[Ref]
Common (1% to 10%): Hyperglycemia, decreased appetite
-Common (1% to 10%): Decreased appetite[Ref]
Grade 2 and grade 3 to 4 hyperglycemia were reported in 4% and less than 1% of patients, respectively.[Ref]
Uncommon (0.1% to 1%): Fractures (excluding fingers and toes), myalgia
Frequency not reported: Myositis, increased BMD, asymptomatic elevated creatine phosphokinase
-Postmarketing reports: Arthralgia, myalgia[Ref]
BMD increased (total hip and lumbar spine) from baseline to week 48 in patients who switched from a tenofovir disoproxil fumarate (DF)-containing antiretroviral regimen to dolutegravir plus rilpivirine compared with patients who continued using a tenofovir DF-containing antiretroviral regimen. BMD declines of at least 5% at the lumbar spine were reported in 2% of patients using this drug and 5% of patients who continued using a tenofovir DF-containing antiretroviral regimen. The long-term clinical relevance of such BMD changes has not been established.
Grade 2 and grade 3 to 4 elevations in creatine phosphokinase were reported in less than 1% and 1% of patients, respectively.
Elevated creatine phosphokinase was reported, primarily associated with exercise.[Ref]
Common (1% to 10%): Rash, pruritus
-Common (1% to 10%): Rash, pruritus
-Common (1% to 10%): Rash
-Postmarketing reports: Severe skin and hypersensitivity reactions (including drug reaction with eosinophilia and systemic symptoms [DRESS])[Ref]
Grade 2 to 3 therapy-related rashes were reported in 3% of patients during phase 3 trials of rilpivirine.[Ref]
Common (1% to 10%): Decreased WBC count, decreased hemoglobin, decreased platelet count
Uncommon (0.1% to 1%): Hypersensitivity
-Uncommon (0.1% to 1%): Hypersensitivity reactions (characterized by rash, constitutional findings, and sometimes organ dysfunction, including liver injury)[Ref]
-Postmarketing reports: Nephrotic syndrome[Ref]
Both components of this drug have increased serum creatinine due to inhibition of tubular secretion of creatinine without affecting renal glomerular function. Increased serum creatinine was reported within the first 4 weeks of therapy and remained stable through 48 weeks. A mean change from baseline of 0.093 mg/dL (range: -0.3 to 0.58 mg/dL) or 8.22 mcmol/L (range: -26.5 to 51.2 mcmol/L) was reported after 48 weeks of therapy; these changes were not considered clinically significant.[Ref]
Frequency not reported: Immune reconstitution syndrome
-Uncommon (0.1% to 1%): Immune reconstitution syndrome
Combination antiretroviral therapy:
-Frequency not reported: Immune reconstitution/reactivation syndrome, autoimmune disorders in the setting of immune reconstitution (e.g., Graves' disease, polymyositis, Guillain-Barre syndrome, autoimmune hepatitis)[Ref]
-Frequency not reported: Decreased basal cortisol, abnormal 250 mcg adrenocorticotropic hormone (ACTH) stimulation test, adrenal insufficiency[Ref]
In the pooled phase 3 trials, at week 96, there was an overall mean change from baseline in basal cortisol of -0.69 mcg/dL in the rilpivirine group, and of -0.02 mcg/dL in the efavirenz group.
In the rilpivirine group, 43 of 588 patients with normal 250 mcg ACTH stimulation test at baseline developed abnormal 250 mcg ACTH stimulation test (peak cortisol level less than 18.1 mcg/dL) during the trial versus 18 of 561 patients in the efavirenz group. Abnormal 250 mcg ACTH stimulation test at week 96 was seen in 14 of the 43 rilpivirine patients and 9 of the 18 efavirenz patients. Overall, there were no serious side effects, deaths, or treatment discontinuations that could clearly be attributed to adrenal insufficiency. Clinical significance of abnormal 250 mcg ACTH stimulation tests in the rilpivirine group has not been established.[Ref]
Frequently asked questions
More about Juluca (dolutegravir / rilpivirine)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (6)
- Drug images
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: antiviral combinations
- En español
Related treatment guides
1. Cerner Multum, Inc. UK Summary of Product Characteristics.
2. Cerner Multum, Inc. Australian Product Information.
3. Product Information. Juluca (dolutegravir-rilpivirine). ViiV Healthcare. 2017.
4. Product Information. Edurant (rilpivirine). Tibotec Pharmaceuticals. 2011.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.